Core Viewpoint - Chow Sang Sang (00116) has reported a positive earnings forecast, leading to a nearly 15% increase in stock price, reflecting strong performance driven by rising gold prices and effective cost control measures [1] Financial Performance - The company expects profit attributable to owners from continuing operations for the six months ending June 30, 2025, to be between HKD 900 million and HKD 920 million, compared to HKD 502 million for the same period in 2024 [1] - The increase in profit is attributed to higher gross margins from gold product sales due to the continuous rise in gold prices [1] Cost Management - Integration of retail networks and other cost control measures have contributed to a reduction in costs, further supporting profit growth [1]

Core Viewpoint - Chow Sang Sang (00116) experienced a nearly 15% increase in stock price following a profit warning, with shares trading at HKD 10.32 and a transaction volume of HKD 2.4458 million [1] Financial Performance - The company expects its profit attributable to owners from continuing operations for the six months ending June 30, 2025, to be between HKD 900 million and HKD 920 million, compared to HKD 502 million for the same period in 2024 [1] - The increase in profit is attributed to higher gross margins from gold product sales due to rising gold prices [1] Cost Management - The integration of retail networks and other cost control measures have contributed to a reduction in costs, further supporting profit growth [1]

Major Events - CSPC Pharmaceutical Group (01093) received clinical trial approval for Dupilumab injection in China [1] - Rongchang Biopharmaceutical (09995) was granted breakthrough therapy designation for RC148 for non-small cell lung cancer by the National Medical Products Administration [1] - China Biologic Products (01177) included LM-302 "CLDN18.2 ADC" in the breakthrough therapy program [1] - Sunshine Oilsands (02012) plans to acquire 51% stake in Noble Technology Limited for HKD 50.91945 million [1] - Galenica Pharmaceutical-B (01672) plans to issue shares at a discount of approximately 9.9%, raising HKD 468 million [1] Financial Performance - Xiaomi Group-W (01810) reported record high revenue and profit for Q2, with attributable profit of HKD 11.904 billion, up 133.51% year-on-year [1] - Pop Mart (09992) announced a mid-term profit of HKD 4.574 billion, a year-on-year increase of 396.5% [1] - Fuyao Glass (03606) reported a half-year net profit of approximately HKD 4.805 billion, up 37.33% year-on-year [1] - China Resources Beer (00291) announced a mid-term profit of HKD 5.789 billion, an increase of 23.04% year-on-year [1] - Kunlun Energy (00135) reported a mid-term profit of HKD 3.161 billion, down 4.36% year-on-year, with a dividend of HKD 0.166 per share [1] - WuXi Biologics (02269) reported a mid-term profit of approximately HKD 2.339 billion, up 56% year-on-year [1] - Sunny Optical Technology (02382) announced a mid-term profit of HKD 1.646 billion, an increase of 52.56% year-on-year [1] - Yixin Group (02858) reported an adjusted net profit of HKD 648 million, up 28% year-on-year [1] - Kangchen Pharmaceutical (01681) reported a mid-term profit of HKD 498 million, up 24.6% year-on-year, maintaining market leadership with its flagship product [1] - Ping An Good Doctor (01833) reported a mid-term profit of HKD 134 million, a year-on-year increase of 136.84% [1] - China Communication Services (02342) reported a mid-term profit of HKD 61.781 million, returning to profitability [1] - XPeng Motors-W (09868) achieved record levels in core business and financial metrics for Q2, with a net loss of HKD 480 million, narrowing by 62.8% year-on-year [1] - Guochuang Tongqiao (02190) reported a mid-term profit of HKD 121 million, up 76% year-on-year [1] - Yanda Pharmaceutical (00512) reported record revenue of HKD 6.107 billion [1] - Jinli Permanent Magnet (06680) reported a mid-term profit of approximately HKD 305 million, up 154.81% year-on-year [1] - Zhaogang Group-W (06676) issued a profit warning, expecting a mid-term profit of approximately HKD 140 million to HKD 180 million, returning to profitability [1] - Longyuan Power (00916) reported a mid-term profit of HKD 3.519 billion, down 14.4% year-on-year [1] - Yancoal Australia (03668) reported a mid-term profit of AUD 16.3 million, down 61.19% year-on-year [1] - SF Holding (06936) reported total revenue of HKD 24.847 billion for July in logistics, supply chain, and international business, up 9.95% year-on-year [1] - Chow Sang Sang (00116) expects a mid-term profit from continuing operations of approximately HKD 900 million to HKD 920 million [1]

格隆汇8月19日｜周生生(0116.HK)公布，预期截至6月底止中期来自持续经营业务的股东应占溢利增至9 亿-9.2亿港元，2024年度同期为5.02亿元。集团表示，期内由于黄金价格持续上涨，黄金商品的销售获 得更高的毛利率。门市网络的整合以及其他成本控制措施令成本降低，也为溢利增长带来贡献。 ...

Core Viewpoint - The company expects a significant increase in profit for the first half of the year, driven by higher gold prices and effective cost control measures [1] Financial Performance - The company anticipates a profit attributable to shareholders from continuing operations between 900 million HKD and 920 million HKD, compared to 502 million HKD in the same period of 2024 [1] - The increase in profit is attributed to higher gross margins from gold product sales due to rising gold prices [1] Cost Management - The integration of retail networks and other cost control measures have contributed to a reduction in costs, further supporting profit growth [1]

相关事件 周生生(00116.HK)盈喜：预计中期持续经营业务纯利录得9亿至9.2亿港元 周生生(00116.HK)拟8月27日 举行董事会会议批准中期业绩 格隆汇8月19日丨周生生(00116.HK)发布公告，截至2025年6月30日止六个月，预计来自持续经营业务的 公司拥有人应占溢利录得介乎9亿港元至9.2亿港元，而2024年同期为5.02亿港元。于该期间，由于黄金 价格持续上涨，黄金商品的销售获得了更高的毛利率。门市网络的整合以及其他成本控制措施令成本降 低，也为溢利增长带来贡献。 ...

于该期间，由于黄金价格持续上涨，黄金商品的销售获得了更高的毛利率。门市网络的整合以及其他成 本控制措施令成本降低，也为溢利增长带来贡献。 周生生(00116)发布公告，集团截至2025年6月30日止六个月的业绩，预计来自持续经营业务的公司拥有 人应占溢利取得介于9亿港元至9.2亿港元，而2024年同期为5.02亿港元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 CHOW SANG SANG HOLDINGS INTERNATIONAL LIMITED 周生生集團國際有限公司* （於百慕達註冊成立之有限公司） * 僅供識別 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及有意投資者，本集團截至 2025 年 6 月 30 日止六個月（「該期間」）之業績，預計來自持續經營業務的本公司擁有人應佔溢利 錄得介乎九億港元至九億二千萬港元，而 2024 年同期為五億二百萬港元。於該期間，由於黃 金價格持續上漲，黃金商品的銷售獲得了更高的毛利率。門市網絡的整合以及其他成本控制 措施令成本降低，也為溢利增長帶來貢獻。 由於本公司正在落實本集團該期間之未經審核綜合中期業績，本公告所載資料是基於本集團 該期間之管理賬目之評估而作出，並未經本公司核數師或審核委員會審閱或審核。本公司將 於 2025 年 8 月 27 日刊發該期間的中期業績公告。 股東及有意投資者在買賣本公 ...

格隆汇8月14日丨周生生(00116.HK)宣布，本公司将于2025年8月27日（星期三）举行董事会会议，藉以 （其中包括）批准刊发本公司及其附属公司截至2025年6月30日止六个月的中期业绩公告，以及考虑派 发中期股息。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 CHOW SANG SANG HOLDINGS INTERNATIONAL LIMITED 周生生集團國際有限公司* （於百慕達註冊成立之有限公司） 股份代號：116 董事會召開日期 周生生集團國際有限公司（「本公司」）董事會宣布，本公司將於 2025 年 8 月 27 日 （星期三）舉行董事會會議，藉以（其中包括）批准刊發本公司及其附屬公司截至 2025 年 6 月 30 日止六個月之中期業績公告，以及考慮派發中期股息。 承董事會命 周生生集團國際有限公司 公司秘書 王君璿 香港，2025 年 8 月 14 日 於本公告日期，本公司執行董事為周永成先生、周敬成醫生、周允成先生及周嘉頴女士； 非執行董事為丁良輝先生；以及獨立非執行董事為陳炳勳醫生、李家麟先生、盧景文博士、 劉文龍先生、許洛聖先生及皮方女士。 * 僅供識別 ...